Published in Lab Business Week, August 29th, 2004
The company believes that the new vial size would be optimal for spreading agent use.
Vicente Anido, Jr., PhD, president and chief executive officer of ISTA stated, "We believe that a smaller vial size that is already reconstituted will greatly enhance the convenience of using Vitrase as a spreading agent by ophthalmologists and increase their familiarity with the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week